Back to Search
Start Over
Verge Genomics begins patient dosing in phase 1 trial of VRG50635, a novel therapeutic for ALS
- Source :
- PharmaBiz. November 2, 2022
- Publication Year :
- 2022
-
Abstract
- Verge Genomics, a clinical-stage, tech-enabled biotechnology company, announced that the first subject has been dosed in a phase 1 clinical trial of VRG50635. VRG50635 is a small molecule inhibitor of [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.724834703